Tumor necrosis factor (TNF) inhibitors, including adalimumab (Humira; AbbVie), etanercept (Enbrel; Amgen), and infliximab (Remicade; Janssen Biotech, Inc), have significantly improved the treatment landscape for chronic inflammatory and autoimmune conditions such as rheumatoid arthritis, ulcerative colitis, Crohn disease, and psoriasis. Although they offer substantial therapeutic benefits, these biologics present unique challenges for patients, particularly concerning immunosuppression, potential adverse effects (AEs), and common misconceptions about “immune boosting.” Pharmacists, with their accessibility and trusted relationships with patients, are uniquely positioned to address these complexities through evidence-based education and proactive counseling.